Literature DB >> 28123639

MicroRNA-221 is involved in the regulation of osteoporosis through regulates RUNX2 protein expression and osteoblast differentiation.

Yinquan Zhang1, Yulei Gao2, Lijun Cai1, Fengning Li2, Yi Lou2, Ning Xu2, Yifan Kang2, Huilin Yang1.   

Abstract

INTRODUCTION: MicroRNAs (miRNAs) has emerged as important factors in osteogenesis and chondrogenesis. This study aimed to determine whether miR-221 is involved in the regulation of osteoporosis and its underlying mechanism.
METHODS: Total RNA was extracted from fresh femoral neck trabecular bone from women undergoing hip replacement due to either osteoporotic fracture (OP group, n = 12) or osteoarthritis in the absence of osteoporosis (Control group, n = 12). Gene expression was quantified using TaqMan quantitative RT-PCR assays and protein production was determined by western blot analysis. The role of miR-221 in osteoblast differentiation was identified by gain or loss function experiment. MiRNA targets were identified using bioinformatics and luciferase reporter assay.
RESULTS: MiR-221 was down-regulated in the osteoporotic samples compared with non-osteoporotic controls, and decreased in a C2C12 cell model of osteogenic differentiation. Overexpression of miR-221 resulted in a decrease in the osteogenic potential, as indicated by the reduced expression levels of key osteoblast markers, including osteocalcin (OC), alkaline phosphatase (ALP) and collagen, type I, α 1 (COL1A1), whereas inhibition of miR-221 promoted the activity of OC, ALP and COL1A1. Then bioinformatic analysis identified potential target sites of the miR-221 located in the 3' untranslated regions of RUNX2. Western blot analysis demonstrated that miR-221 inhibited RUNX2 gene expression. Furthermore, dual-luciferase reporter assays confirmed that RUNX2 was a direct target of miR-221. Rescue experiments showed that overexpression of RUNX2 significantly attenuated the effect of miR-221 on osteoblast markers providing strong evidence that miR-221 mediated the osteoblast differentiation by targeting RUNX2.
CONCLUSIONS: Taken together, these data implied that miR-221 played an important part in osteoporosis through regulating RUNX2 expression and osteoblast differentiation.

Entities:  

Keywords:  Osteoporosis; RUNX2; microRNA-221; osteoblast; osteogenic differentiation

Year:  2017        PMID: 28123639      PMCID: PMC5250709     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  32 in total

Review 1.  Therapeutic approaches to bone diseases.

Authors:  G A Rodan; T J Martin
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

Review 2.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

3.  Emodin regulates bone remodeling by inhibiting osteoclastogenesis and stimulating osteoblast formation.

Authors:  Ju-Young Kim; Yoon-Hee Cheon; Sung Chul Kwak; Jong Min Baek; Kwon-Ha Yoon; Myeung Su Lee; Jaemin Oh
Journal:  J Bone Miner Res       Date:  2014-07       Impact factor: 6.741

Review 4.  Non-coding RNAs: Epigenetic regulators of bone development and homeostasis.

Authors:  Mohammad Q Hassan; Coralee E Tye; Gary S Stein; Jane B Lian
Journal:  Bone       Date:  2015-05-31       Impact factor: 4.398

5.  Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts.

Authors:  T Komori; H Yagi; S Nomura; A Yamaguchi; K Sasaki; K Deguchi; Y Shimizu; R T Bronson; Y H Gao; M Inada; M Sato; R Okamoto; Y Kitamura; S Yoshiki; T Kishimoto
Journal:  Cell       Date:  1997-05-30       Impact factor: 41.582

6.  Relative abundance of different cadherins defines differentiation of mesenchymal precursors into osteogenic, myogenic, or adipogenic pathways.

Authors:  C S Shin; F Lecanda; S Sheikh; L Weitzmann; S L Cheng; R Civitelli
Journal:  J Cell Biochem       Date:  2000-06-12       Impact factor: 4.429

7.  A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans.

Authors:  Hui Li; Hui Xie; Wei Liu; Rong Hu; Bi Huang; Yan-Fei Tan; Kang Xu; Zhi-Feng Sheng; Hou-De Zhou; Xian-Ping Wu; Xiang-Hang Luo
Journal:  J Clin Invest       Date:  2009-11-16       Impact factor: 14.808

Review 8.  China's rapidly aging population creates policy challenges in shaping a viable long-term care system.

Authors:  Zhanlian Feng; Chang Liu; Xinping Guan; Vincent Mor
Journal:  Health Aff (Millwood)       Date:  2012-12       Impact factor: 6.301

9.  MiR-221 and miR-26b Regulate Chemotactic Migration of MSCs Toward HGF Through Activation of Akt and FAK.

Authors:  Aisi Zhu; Naixin Kang; Lihong He; Xianyang Li; Xiaojing Xu; Huanxiang Zhang
Journal:  J Cell Biochem       Date:  2015-11-24       Impact factor: 4.429

10.  Role of microRNA221 in regulating normal mammary epithelial hierarchy and breast cancer stem-like cells.

Authors:  Jia Ke; Zhiju Zhao; Su-Hyung Hong; Shoumin Bai; Zhen He; Fayaz Malik; Jiahui Xu; Lei Zhou; Weilong Chen; Rachel Martin-Trevino; Xiaojian Wu; Ping Lan; Yongju Yi; Christophe Ginestier; Ingrid Ibarra; Li Shang; Sean McDermott; Tahra Luther; Shawn G Clouthier; Max S Wicha; Suling Liu
Journal:  Oncotarget       Date:  2015-02-28
View more
  30 in total

1.  A preliminary analysis of microRNA profiles in the subchondral bone between Kashin-Beck disease and primary knee osteoarthritis.

Authors:  Guang-Hui Zhao; Lei Yang; Mikko J Lammi; Xiong Guo
Journal:  Clin Rheumatol       Date:  2019-05-06       Impact factor: 2.980

2.  A systematic review of miRNAs as biomarkers in osteoporosis disease.

Authors:  Mandana Hasanzad; Maryam Hassani Doabsari; Marzieh Rahbaran; Pantea Banihashemi; Fatemeh Fazeli; Mehrnoush Ganji; Shahrzad Manavi Nameghi; Negar Sarhangi; Shekoufeh Nikfar; Hamid Reza Aghaei Meybodi
Journal:  J Diabetes Metab Disord       Date:  2021-08-27

3.  Overexpression of microRNA-221 promotes the differentiation of stem cells from human exfoliated deciduous teeth to neurons through activation of Wnt/β-catenin pathway via inhibition of CHD8.

Authors:  Bing Wen; Chenjiang He; Qin Zhang; Fanglin Zhang; Na Li; Yan Pan; Mengting Deng; Yue Wang; Jianping Li; Jiaxuan Qiu
Journal:  Cell Cycle       Date:  2020-11-17       Impact factor: 4.534

4.  MICROmanagement of Runx2 Function in Skeletal Cells.

Authors:  Benjamin J Wildman; Tanner C Godfrey; Mohammad Rehan; Yuechuan Chen; Lubana H Afreen; Quamarul Hassan
Journal:  Curr Mol Biol Rep       Date:  2019-01-24

5.  Calycosin Orchestrates Osteogenesis of Danggui Buxue Tang in Cultured Osteoblasts: Evaluating the Mechanism of Action by Omics and Chemical Knock-out Methodologies.

Authors:  Amy G W Gong; Ran Duan; Huai Y Wang; Tina T X Dong; Karl W K Tsim
Journal:  Front Pharmacol       Date:  2018-02-01       Impact factor: 5.810

Review 6.  Osteoblast Role in Rheumatic Diseases.

Authors:  Addolorata Corrado; Nicola Maruotti; Francesco Paolo Cantatore
Journal:  Int J Mol Sci       Date:  2017-06-15       Impact factor: 5.923

7.  Genetic Polymorphism of miR-196a-2 is Associated with Bone Mineral Density (BMD).

Authors:  Irma Karabegović; Silvana Maas; Carolina Medina-Gomez; Maša Zrimšek; Sjur Reppe; Kaare M Gautvik; André G Uitterlinden; Fernando Rivadeneira; Mohsen Ghanbari
Journal:  Int J Mol Sci       Date:  2017-11-25       Impact factor: 5.923

8.  MiR-23a targets RUNX2 and suppresses ginsenoside Rg1-induced angiogenesis in endothelial cells.

Authors:  Xiao-Dong Wu; Ting Guo; Li Liu; Chao Wang; Kun Zhang; Han-Qiang Liu; Feng Wang; Wen-Dong Bai; Meng-Yao Zhang
Journal:  Oncotarget       Date:  2017-07-22

9.  Bone-targeted lncRNA OGRU alleviates unloading-induced bone loss via miR-320-3p/Hoxa10 axis.

Authors:  Ke Wang; Yixuan Wang; Zebing Hu; Lijun Zhang; Gaozhi Li; Lei Dang; Yingjun Tan; Xinsheng Cao; Fei Shi; Shu Zhang; Ge Zhang
Journal:  Cell Death Dis       Date:  2020-05-19       Impact factor: 8.469

10.  MicroRNA-495 Inhibits New Bone Regeneration via Targeting High Mobility Group AT-Hook 2 (HMGA2).

Authors:  Zhao Tian; Haizhen Zhou; Yuben Xu; Jie Bai
Journal:  Med Sci Monit       Date:  2017-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.